Astrazeneca (AZN) Inventory Average (2009 - 2026)

Astrazeneca (AZN) has reported Inventory Average for 18 consecutive years, with $6.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory Average rose 17.5% year-over-year to $6.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 17.5% YoY), while the FY2025 annual figure was $5.9 billion, up 10.58% from the prior year.
• Inventory Average came in at $6.6 billion for Q1 2026 at Astrazeneca, roughly flat from $6.6 billion in the prior quarter.
• The five-year high for Inventory Average was $8.3 billion in Q1 2022, with the low at $4.8 billion in Q1 2023.
• Average Inventory Average over 5 years is $5.9 billion, with a median of $5.6 billion recorded in 2025.
• The largest YoY upside for Inventory Average was 156.81% in 2022 against a maximum downside of 49.89% in 2022.
• Year by year, Inventory Average stood at $4.9 billion in 2022, then advanced by 9.6% to $5.4 billion in 2023, then advanced by 2.18% to $5.5 billion in 2024, then advanced by 20.09% to $6.6 billion in 2025, then declined by 0.17% to $6.6 billion in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $6.6 billion, $6.6 billion, and $6.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.